Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie

NEW YORK, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally…

This report seeks to deliver an in-depth analysis of the worldwide oncology pharmaceuticals (cancer medications) market. It includes a thorough…

Quantum computing represents the next frontier in computational power. Once developed, these systems could solve complex problems in drug development,…

AstraZeneca and Daiichi Sankyo voluntarily withdraw regulatory filing for Dato-DXd in nonsquamous non-small cell lung cancer in the European Union.…

NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…

Kulmbach (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von…

- Proprietary data and samples from TRACERx and Achilles’ Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the…

DJ Astrazeneca/Daiichi Sankyo ziehen EU-Zulassungsantrag für Lungenkrebsmittel zurück Von Najat Kantouar Dow Jones--Die Pharmakonzerne AstraZeneca und Daiichi Sankyo ziehen ihren…

AstraZeneca PLC (LSE:AZN) has pulled a marketing authorisation application for its key lung cancer drug in the European Union. FTSE…

24 December 2024 Datopotamab deruxtecan application in the EU for patients with advanced nonsquamous non-small cell lung cancer voluntarily withdrawn AstraZeneca and Daiichi Sankyo…